{
  "id": 16392868,
  "title": "Forget the FDA Delay: 3 Reasons Exelixis Is Still a Buy",
  "url": "https://urgent.news/2026/10/24/forget-the-fda-delay-3-reasons-exelixis-is-still-a-buy-16392868",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-24T23:20:00.000Z",
  "source": {
    "name": "Nasdaq Markets",
    "slug": "nasdaq-markets",
    "url": "https://www.nasdaq.com/articles/forget-fda-delay-3-reasons-exelixis-still-buy"
  },
  "original_language": "en",
  "account": null,
  "summary": "Key PointsRegulators in the U.S. extended the review period for Exelixis’ request to approve a new cancer drug.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Motley Fool",
        "title": "Forget the FDA Delay: 3 Reasons Exelixis Is Still a Buy",
        "url": "https://urgent.news/2026/10/24/forget-the-fda-delay-3-reasons-exelixis-is-still-a-buy",
        "published": "2026-10-24T23:00:00.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}